JP2023542092A5 - - Google Patents
Info
- Publication number
- JP2023542092A5 JP2023542092A5 JP2023515682A JP2023515682A JP2023542092A5 JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5 JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023515682 A JP2023515682 A JP 2023515682A JP 2023542092 A5 JP2023542092 A5 JP 2023542092A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076818P | 2020-09-10 | 2020-09-10 | |
| US63/076,818 | 2020-09-10 | ||
| US202163164255P | 2021-03-22 | 2021-03-22 | |
| US63/164,255 | 2021-03-22 | ||
| PCT/EP2021/075022 WO2022053658A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542092A JP2023542092A (ja) | 2023-10-05 |
| JP2023542092A5 true JP2023542092A5 (https=) | 2024-09-18 |
| JPWO2022053658A5 JPWO2022053658A5 (https=) | 2024-09-18 |
Family
ID=77914295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515682A Pending JP2023542092A (ja) | 2020-09-10 | 2021-09-10 | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230312759A1 (https=) |
| EP (1) | EP4210745A1 (https=) |
| JP (1) | JP2023542092A (https=) |
| KR (1) | KR20230066392A (https=) |
| AU (1) | AU2021342343A1 (https=) |
| BR (1) | BR112023004319A2 (https=) |
| CA (1) | CA3192256A1 (https=) |
| IL (1) | IL301100A (https=) |
| MX (1) | MX2023002541A (https=) |
| WO (1) | WO2022053658A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| AU2021339006A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma |
| IL301085A (en) | 2020-09-10 | 2023-05-01 | Genmab As | A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| EP4210742A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| CN121358750A (zh) | 2023-05-15 | 2026-01-16 | 金麦安博股份有限公司 | 高度纯化的艾可瑞妥单抗组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| MX373245B (es) | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| BR112020015052A2 (pt) | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
-
2021
- 2021-09-10 MX MX2023002541A patent/MX2023002541A/es unknown
- 2021-09-10 AU AU2021342343A patent/AU2021342343A1/en active Pending
- 2021-09-10 IL IL301100A patent/IL301100A/en unknown
- 2021-09-10 JP JP2023515682A patent/JP2023542092A/ja active Pending
- 2021-09-10 KR KR1020237011606A patent/KR20230066392A/ko active Pending
- 2021-09-10 WO PCT/EP2021/075022 patent/WO2022053658A1/en not_active Ceased
- 2021-09-10 CA CA3192256A patent/CA3192256A1/en active Pending
- 2021-09-10 US US18/025,208 patent/US20230312759A1/en active Pending
- 2021-09-10 EP EP21777656.6A patent/EP4210745A1/en active Pending
- 2021-09-10 BR BR112023004319A patent/BR112023004319A2/pt unknown
- 2021-12-22 US US17/559,965 patent/US20220112309A1/en not_active Abandoned